Elekta stock tracks solid earnings as oncology orders grow

Elekta stock, tied to the Swedish precision radiation-therapy group Elekta AB (ISIN SE0000163628), has been shaped in recent months by resilient oncology equipment demand and steady profitability, as shown in the companys latest reported fiscal results and recent market data up to 30 April 2024.

Revenue tops SEK 15 billion

According to data from Elekta ABs published fiscal reporting for its financial year ended 30 April 2024, the company generated net sales of about SEK 15.0 billion for the period, broadly in line with the prior year but supported by strong equipment deliveries in key markets.

In the same fiscal 2023/24 reporting framework, Elekta AB disclosed an EBIT or operating result of roughly SEK 1.7 billion, which translated into an operating margin in the low double-digit percentage range and underscored the companys ability to maintain profitability despite input-cost inflation and currency headwinds.

Order intake rises about 10 percent

Within Elekta ABs fiscal 2023/24 figures, order intake stood out as a growth driver: total orders for the year reached around SEK 17.0 billion, representing an increase of approximately 10 percent compared with the previous fiscal year and signaling continued investment by hospitals in radiation-therapy systems and software.

This double-digit order-intake growth meant that Elekta AB ended the fiscal year with a book-to-bill ratio above one times, indicating that new orders exceeded revenue recognized over the same period and providing visibility for future installations and service activity.

Oncology systems underpin growth

Elekta ABs revenue mix in fiscal 2023/24 remained dominated by radiation-therapy solutions, with linear accelerators, treatment-planning software, and associated services contributing the bulk of net sales and underpinning the SEK 15.0 billion revenue line.

The roughly SEK 17.0 billion in orders during fiscal 2023/24 also reflected robust demand for replacement linacs and upgrades in both developed markets and emerging economies, helping to offset pricing pressure and reimbursement constraints faced by some customers.

Market value and stock context

Based on recent market data available for 30 April 2024, Elekta AB carried a market capitalization in the region of SEK 45 billion, positioning the company as a mid-cap medical-technology player within the Stockholm equity market and providing liquidity for institutional and retail investors.

With net sales near SEK 15.0 billion for fiscal 2023/24 and a market capitalization around SEK 45 billion as of late April 2024, Elekta AB traded at a price-to-sales ratio close to three times on that basis, a valuation level that investors often compare with other listed radiation-therapy and medical-device manufacturers.

Elekta Unity expands precision offering

One of the flagship products supporting Elekta ABs order intake is the Elekta Unity magnetic resonance radiation therapy platform, which combines MRI imaging with a linear accelerator to allow clinicians to visualize tumors during treatment and adapt plans in near real time.

In recent fiscal disclosures around 2023/24, Elekta AB reported that the installed base of Elekta Unity systems continued to grow from the prior year, contributing to both equipment revenue within the approximately SEK 15.0 billion net sales total and to high-margin service contracts that will be recognized in future periods.

Stock level and trading venue

Elekta stock is listed on Nasdaq Stockholm, where it trades in Swedish kronor and often features daily turnover in the hundreds of thousands of shares, offering investors direct exposure to global demand for radiation-therapy and oncology software solutions.

At a market capitalization of roughly SEK 45 billion as of 30 April 2024 and net sales of around SEK 15.0 billion in fiscal 2023/24, Elekta stock offers a combination of established installed base, growing order backlog of about SEK 17.0 billion, and exposure to long-term trends in cancer treatment.